MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
MADRIGAL PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$447.09−2.65 (-0.59%)
Close on Oct 19, 2026
- Market cap
- $13.03B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
24M of 23M shares
Institutional holders
413
79 new, 41 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 202 sales
Net sold $81.48M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Behzad Aghazadeh | 2,288,888 | 9.90% | 13G (passive) amendment | Dec 31, 2023 |
| Felix J. Baker | 2,070,544 | 9.99% | 13D (active) amendment | Mar 21, 2024 |
| Janus Henderson Group PLC | 2,018,647 | 8.80% | 13G (passive) amendment | Mar 31, 2026 |
| RTW Investments, LP | 1,993,687 | 9.20% | 13G (passive) | Sep 30, 2024 |
| Paul A Friedman, M.D. | 1,814,831 | 7.80% | 13D (active) amendment | Dec 10, 2025 |
| Rebecca Taub, M.D. | 1,814,831 | 7.80% | 13D (active) amendment | Dec 10, 2025 |
| Paulson & Co. Inc. | 1,392,188 | 6.10% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MDGL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 2,143,131 | 9.28% | $1.15B | +1,430 | 5.77% |
| Rtw Investments, LP | 1,993,687 | 8.63% | $1.07B | – | 9.14% |
| Jupiter Topco LLC | 1,936,099 | 8.38% | $1.04B | New | 0.42% |
| Avoro Capital Advisors LLC | 1,833,333 | 7.94% | $984.41M | +15,152 | 8.84% |
| Paulson & Co. Inc. | 1,340,020 | 5.80% | $719.52M | −52,168 | 27.94% |
| BlackRock, Inc. | 1,200,770 | 5.20% | $644.75M | −359,195 | 0.01% |
| Vanguard Capital Management LLC | 835,668 | 3.62% | $448.71M | +8,524 | 0.01% |
| Wellington Management Group Llp | 825,714 | 3.57% | $443.37M | +130,756 | 0.08% |
| Vanguard Portfolio Management LLC | 781,731 | 3.38% | $419.75M | −59,414 | 0.02% |
| State Street Corp | 527,057 | 2.28% | $283.00M | −82,468 | 0.01% |
| Citadel Advisors LLC | 507,233 | 2.20% | $272.36M | +53,390 | 0.03% |
| UBS Group AG | 401,708 | 1.74% | $215.70M | +283,929 | 0.03% |
| Geode Capital Management, LLC | 374,880 | 1.62% | $201.34M | −80,990 | 0.01% |
| FMR LLC | 356,201 | 1.54% | $191.26M | −155,527 | 0.01% |
| William Blair Investment Management, LLC | 324,123 | 1.40% | $174.04M | −16,396 | 0.52% |
| Invesco Ltd. | 301,435 | 1.30% | $161.86M | −28,084 | 0.01% |
| Armistice Capital, LLC | 288,000 | 1.25% | $154.64M | +23,417 | 1.89% |
| Lord, Abbett & Co. LLC | 281,500 | 1.22% | $151.15K | +38,774 | 0.43% |
| Assenagon Asset Management S.A. | 248,428 | 1.08% | $133.39M | +232,395 | 0.08% |
| Goldman Sachs Group Inc | 246,280 | 1.07% | $132.24M | −31,091 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 413 | 24M | 100.0% | 79 / 144 | 131 / 41 | 5M | 3M |
| Q1 2026 | 380 | 24M | 100.0% | 63 / 130 | 130 / 64 | 4M | 2M |
| Q4 2025 | 387 | 24M | 100.0% | 85 / 137 | 113 / 41 | 2M | 2M |
| Q3 2025 | 352 | 23M | 100.0% | 87 / 107 | 107 / 37 | 3M | 3M |
| Q2 2025 | 305 | 24M | 100.0% | 38 / 107 | 110 / 51 | 2M | 2M |
| Q1 2025 | 321 | 24M | 100.0% | 73 / 110 | 91 / 32 | 2M | 1M |
| Q4 2024 | 283 | 23M | 99.4% | 67 / 95 | 77 / 37 | 2M | 2M |
| Q3 2024 | 257 | 23M | 98.4% | 45 / 86 | 83 / 43 | 3M | 2M |
| Q2 2024 | 257 | 23M | 99.2% | 49 / 111 | 64 / 55 | 4M | 2M |
| Q1 2024 | 266 | 22M | 94.5% | 74 / 87 | 78 / 33 | 4M | 3M |
| Q4 2023 | 226 | 20M | 86.5% | 56 / 92 | 57 / 32 | 5M | 2M |
| Q3 2023 | 205 | 17M | 75.2% | 37 / 89 | 54 / 38 | 4M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MDGL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 584,997 | 2.53% | $314.11M | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Fund | 563,117 | 2.44% | $263.16M | 0.69% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 423,142 | 1.83% | $227.21M | 0.12% | Jun 30, 2026 |
| Janus Henderson Forty Fund | 338,602 | 1.47% | $181.81M | 0.76% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 243,683 | 1.05% | $130.85M | 0.28% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund | 233,269 | 1.01% | $125.25M | 0.56% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 216,882 | 0.94% | $116.45M | 0.12% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 211,251 | 0.91% | $113.43M | 1.06% | Jun 30, 2026 |
| Vanguard Explorer Fund | 190,140 | 0.82% | $88.86M | 0.40% | Jul 31, 2026 |
| Janus Henderson Contrarian Fund | 168,259 | 0.73% | $90.35M | 1.65% | Jun 30, 2026 |
| iShares Biotechnology ETF | 153,736 | 0.67% | $82.55M | 0.91% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 145,364 | 0.63% | $78.05M | 1.34% | Jun 30, 2026 |
| Lord Abbett Growth Leaders Fund | 140,436 | 0.61% | $65.63M | 0.88% | Jul 31, 2026 |
| Invesco Discovery Fund | 119,197 | 0.52% | $59.27M | 0.76% | May 31, 2026 |
| iShares Russell Mid-Cap Growth ETF | 105,779 | 0.46% | $56.80M | 0.26% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William John Sibold | President and CEO, Director | 202,801 | 0.88% | Sep 11, 2026 |
| Shannon T. Kelley | General Counsel | 11,474 | 0.05% | Aug 20, 2026 |
| David Soergel | Chief Medical Officer | 10,033 | 0.04% | Jun 1, 2026 |
| Carole Huntsman | Chief Commercial Officer | 12,692 | 0.05% | Mar 6, 2026 |
| Mardi Dier | EVP and CFO | 12,850 | 0.06% | Mar 6, 2026 |
| Rita Thakkar | Chief Accounting Officer | 2,398 | 0.01% | Jan 20, 2026 |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 10,918 | 0.05% | Mar 7, 2025 |
| John C. Reed | Director | 647 | 0.00% | Aug 18, 2026 |
| Jacqualyn A. Fouse | Director | 1,551 | 0.01% | Jun 18, 2026 |
| Daniel J. Brennan | Director | 1,371 | 0.01% | Jun 18, 2026 |
| Rebecca Taub | Director | 1,108,207 | 4.80% | Jun 18, 2026 |
| 667, L.P. | Director | 1,669,016 | 7.22% | Jun 18, 2026 |
| Bros. Advisors Lp Baker | Director | 1,793,403 | 7.76% | Jun 18, 2026 |
| Julian Baker | Director | 1,612,339 | 6.98% | Jun 18, 2026 |
| Felix Baker | Director | 1,843,469 | 7.98% | Jun 18, 2026 |
| Brothers Life Sciences LP Baker | Director | 1,948,876 | 8.44% | Jun 18, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | 1,947,968 | 8.43% | Jun 18, 2026 |
| James M. Daly | Director | 3,081 | 0.01% | Jun 18, 2026 |
| Richard S. Levy | Director | 22,469 | 0.10% | Jun 18, 2026 |
| Paul A. Friedman | Director | 855,884 | 3.70% | Jan 13, 2026 |
| Kenneth Bate | Director | 8,896 | 0.04% | Nov 7, 2025 |
| Fred B. Craves | Director | 390,028 | 1.69% | Mar 14, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −106 | $534.06 | $56.61K | 202,801 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −120 | $546.38 | $65.57K | 197,746 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −761 | $544.83 | $414.62K | 197,866 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,539 | $544.02 | $837.25K | 198,627 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,202 | $542.60 | $652.21K | 200,166 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −368 | $541.64 | $199.32K | 201,368 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −687 | $540.59 | $371.39K | 201,736 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −160 | $537.62 | $86.02K | 202,423 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −218 | $535.94 | $116.83K | 202,583 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −60 | $533.09 | $31.99K | 202,907 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −362 | $541.65 | $196.08K | 203,127 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −505 | $540.19 | $272.80K | 203,489 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −215 | $539.03 | $115.89K | 203,994 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −520 | $538.30 | $279.92K | 204,209 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −640 | $537.17 | $343.79K | 204,729 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −1,040 | $536.11 | $557.55K | 205,369 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −644 | $535.27 | $344.71K | 206,409 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −396 | $534.20 | $211.54K | 207,053 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −512 | $533.09 | $272.94K | 207,449 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −368 | $531.99 | $195.77K | 207,961 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −522 | $530.23 | $276.78K | 208,329 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −347 | $529.27 | $183.66K | 208,851 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −131 | $527.88 | $69.15K | 209,198 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −160 | $542.55 | $86.81K | 202,967 |
| Shannon T. Kelley General Counsel | Aug 17, 2026 | Sale | −664 | $514.97 | $341.94K | 11,474 |
| John C. Reed Director | Aug 15, 2026 | Award | +647 | – | – | 647 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −140 | $542.75 | $75.99K | 211,689 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −110 | $543.79 | $59.82K | 211,579 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −275 | $545.71 | $150.07K | 210,759 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −269 | $547.08 | $147.16K | 210,490 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −680 | $547.70 | $372.44K | 209,810 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −47 | $548.87 | $25.80K | 209,763 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −153 | $550.01 | $84.15K | 209,610 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −1 | $550.72 | $551 | 209,609 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −280 | $555.05 | $155.41K | 209,329 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −545 | $544.71 | $296.87K | 211,034 |
| William John Sibold President and CEO, Director | Jul 17, 2026 | Option exercise | +50,000 | – | – | 211,829 |
| Daniel J. Brennan Director | Jun 17, 2026 | Award | +404 | – | – | 1,371 |
| James M. Daly Director | Jun 17, 2026 | Award | +454 | – | – | 3,081 |
| Richard S. Levy Director | Jun 17, 2026 | Award | +454 | – | – | 22,469 |
| Jacqualyn A. Fouse Director | Jun 17, 2026 | Award | +454 | – | – | 1,551 |
| Brothers Life Sciences LP Baker Director | Jun 17, 2026 | Award | +908 | – | – | 1,948,876 |
| Brothers Life Sciences LP Baker Director | Jun 17, 2026 | Award | +908 | – | – | 203,721 |
| Rebecca Taub Director | Jun 17, 2026 | Award | +454 | – | – | 452,667 |
| David Soergel Chief Medical Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −1,042 | $495.74 | $516.56K | 10,033 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −320 | $508.24 | $162.64K | 27,337 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −40 | $506.68 | $20.27K | 27,657 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −151 | $510.36 | $77.06K | 27,186 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −610 | $511.40 | $311.95K | 26,576 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −439 | $512.50 | $224.99K | 26,137 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −40 | $512.97 | $20.52K | 26,097 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −343 | $514.67 | $176.53K | 25,754 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −657 | $515.92 | $338.96K | 25,097 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −723 | $516.87 | $373.70K | 24,374 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −1,497 | $517.59 | $774.83K | 22,877 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −782 | $518.76 | $405.67K | 22,095 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −80 | $519.98 | $41.60K | 22,015 |
| David Soergel Chief Medical Officer | May 18, 2026 | Sale | −844 | $515.90 | $435.42K | 11,075 |
| Carole Huntsman Chief Commercial Officer | Mar 6, 2026 | Sale | −419 | $431.94 | $180.98K | 12,692 |
| Rebecca Taub Director | Mar 6, 2026 | Sale | −491 | $431.94 | $212.08K | 452,213 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Friedman Paul Director | Sep 28, 2026 | 50,000 | $25.83M | Sep 28, 2026 | Exercise of Stock Options |
| Sibold William Director, Officer | Sep 11, 2026 | 5,221 | $2.78M | Sep 11, 2026 | Restricted Stock Units |
| John Sibold William Officer and Director | Sep 9, 2026 | 6,362 | $3.40M | Sep 9, 2026 | Restricted Stock Unit Grant |
| Kelley Shannon Officer | Aug 20, 2026 | 664 | $337.02K | Aug 17, 2026 | Restricted Stock Unit Grant |
| Sibold William Officer and Director | Jul 20, 2026 | 2,500 | $1.38M | Jul 20, 2026 | Performance Restricted Stock Unit Grant |
| Soergel David Officer | Jun 1, 2026 | 1,042 | $518.16K | Jun 1, 2026 | Restricted Stock Units |
| Levy Richard Director | May 22, 2026 | 5,682 | $2.92M | May 22, 2026 | Previously Exercised Stock Options |
| Soergel David Officer | May 18, 2026 | 844 | $441.99K | May 18, 2026 | Restricted Stock Unit Grant |
| Kelley Shannon Officer | Mar 6, 2026 | 360 | $158.16K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Huntsman Carole Officer | Mar 6, 2026 | 419 | $184.08K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Sibold William Officer and Director | Mar 6, 2026 | 1,663 | $730.62K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Dier Mardi Officer | Mar 6, 2026 | 646 | $283.81K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Taub Rebecca Director | Mar 6, 2026 | 491 | $215.72K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Dier Mardi Officer | Mar 6, 2026 | 1,336 | $586.96K | Mar 6, 2026 | Restricted Stock Units |
| Dier Mardi Officer | Mar 2, 2026 | 1,183 | $511.06K | Mar 2, 2026 | Restricted Stock Unit Grant |